> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Orphan Status for Akari’s Guillain Barr Therapy
- URL: https://www.fdaweb.com/fda-orphan-status-for-akaris-guillain-barr-therapy/
- Published: 2016-05-13T12:00:00.000Z
- Updated: 2026-09-14T21:02:49.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135662

FDA has granted Akari Therapeutics an orphan drug designation for coversin, a recombinant protein inhibitor of complement factor 5 for treating Guillain Barr Syndrome. The company says the second-generation complement inhibitor is intended to act on complement component-C5, preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex).

Guillain Barr syndrome is an acute immune-mediated post infectious polyneuropathy where the immune system is triggered into attacking peripheral nerves, leading to progressive, fairly symmetric muscle weakness and paralysis accompanied by absent or depressed deep tendon reflexes, according to the company. In animal models, coversin has been shown to provide protection against such effects, it says.